Clinical Trial Update: A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) [Phase 2]

View source ↗

Summary

Phase 2 trial of PF-04958242 for cognitive impairment in schizophrenia was terminated in 2017; results posted but no further development indicated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia

Drugs mentioned

• PF-04958242

Snippet

Sponsor: Biogen | Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Status: TERMINATED | Results posted: 2017-10-04